Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
Sharon Walmsley(University Health Network), Mounir Ait‐Khaled(ViiV Healthcare (United Kingdom)), Thomas A. Lutz(ZHAW Zurich University of Applied Sciences), Don Smith(Albion Centre), Richard Grove(GlaxoSmithKline (United Kingdom)), Gilda Bontempo, Brian Wynne(Research Triangle Park Foundation), Michelle Kisare(ViiV Healthcare (United Kingdom)), Pedro Cahn(Hospital San Juan de Dios), Karine Lacombe(Inserm), Princy Kumar(Georgetown University), Riya Moodley(ViiV Healthcare (United Kingdom)), Andrew Clark(ViiV Healthcare (Spain)), Bryn Jones(ViiV Healthcare (United Kingdom)), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Chinyere Okoli(ViiV Healthcare (United Kingdom))
Cited by 11
Related Papers
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2012|2.5k
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2008|1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777